Ignite Creation Date:
2024-05-06 @ 8:21 PM
Last Modification Date:
2024-10-26 @ 3:25 PM
Study NCT ID:
NCT06341764
Status:
RECRUITING
Last Update Posted:
2024-04-02
First Post:
2023-10-30
Brief Title:
Neo-adjuvant Chemo and Immunotherapy in The Pre-operAtive Treatment of Locally Advanced cholangIOcarciNoma
Sponsor:
National Cancer Institute Naples
Organization:
National Cancer Institute Naples
Study Overview
Official Title:
Neo-adjuvant Chemo and Immunotherapy With Durvalumab MEDI4736 and Tremelimumab MEDI1123 In The Pre-operAtive Treatment of Locally Advanced cholangIOcarciNoma an Exploratory and Translational Study
Status:
RECRUITING
Status Verified Date:
2023-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Neoadjuvant chemo- and immunotherapy ameliorate the recurrence rate of cholangiocarcinoma CCA at 12 months after surgery
Detailed Description:
Multicenter single arm phase II study
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 723 | OTHER | IRCCS INT G Pascale | None |